Dr. Elias Discusses the Future of Androgen Receptors in Breast Cancer
Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado Denver, discusses the future of androgen receptors in breast cancer.
Currently, there is a maturing, randomized phase II study of exemestane, plus or minus, enzalutamide in AR-positive breast cancer, says Elias.
Data have been collected in triple-negative breast cancer with enzalutamide, and Elias says it is fairly compelling. He adds that there is potential action on more aggressive, triple-negative breast cancer, and Elias believes combinations will be particularly significant. Examples include combinations with anti-estrogen therapy and everolimus, anti-estrogen therapy and palbociclib, CDK4/6 inhibitors with enzalutamide, etc.
Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses the future of androgen receptors in breast cancer.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
